Marketed Products

A predictive medicine product for hereditary breast and ovarian cancer.

BRACAnalysis® assesses a woman's risk of developing breast or ovarian cancer based on detection of mutations in the BRCA1 and BRCA2 genes. This test has become the standard of care in identification of individuals with hereditary breast and ovarian cancer and is reimbursed by insurance.

A predictive medicine product for hereditary and uterine colorectal cancer.

COLARIS® assesses a persons risk of developing colorectal and a woman's risk of developing uterine cancer. COLARIS® detects disease-causing mutations in three genes, MLH1, MSH2, and MSH6, which are responsible for the majority of hereditary nonpolyposis colorectal cancer.

A predictive medicine product for adenomatous polyposis colon cancer syndromes.

COLARIS AP® assesses a persons risk of developing hereditary colorectal polyps and cancer. COLARIS AP® detects mutations in the APC and MYH genes, which cause adenomatous polyposis colon cancer syndromes, including familial adenomatous polyposis (FAP), attenuated FAP (AFAP), and MYH -associated polyposis (MAP).

A predictive medicine product for hereditary melanoma.

MELARIS® assesses a persons risk of developing melanoma. This test detects inherited mutations in the p16 gene (also called CDKN2A or INK4A), which occur in up to 40% of families with hereditary melanoma.

A personalized medicine product to measure a patient's exposure to 5-FU chemotherapy.

OnDose™ provides ongoing insight to help the physician proactively adjust and optimize dosing to optimize efficacy and reduce toxicity, and allows physicians to make a pharmacokinetic determination of the Area Under the Curve (AUC) for each infusion cycle.

Click here for a video about OnDose™ presented by leading oncology expert, Dr. Edward Chu.

A personalized medicine product to assess the status of the PTEN gene.

PREZEON™ assesses loss of PTEN function in cancer patients, which is associated with more aggressive disease progression and poorer survival. The PTEN gene is a major antioncogene that plays a critical role in cell signaling pathways that are the target of cancer drugs, such as EGFR inhibitors and mTOR inhibitors.

A personalized medicine product to predict toxicity to 5-FU-based chemotherapy.

TheraGuide® 5-FU assesses a person's risk of developing a severe toxic reaction to 5-FU-based chemotherapy. It detects variations in 2 genes, dihydropyrimidine dehydrogenase (DPYD) and thymidylate synthetase (TYMS), that are responsible for a significant portion of serious adverse reactions to 5-FU-based therapy.